stockportfolio.pro
Start 7-day free trial
Insulet Corporation (PODD)
Healthcare · Medical Devices · NasdaqGS
Insulet Corporation revenue & earnings (annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.70B | $1.31B |
| Gross profit | $0 | $0 | $0 | $0 |
| Net income | $247.10M | $418.30M | $206.30M | $4.60M |
See the full financials for Insulet Corporation
Full income statement, balance sheet and cash flow (28+ line items across multiple years), an interactive price & market-cap chart, valuation ratios, and the ability to track PODD in your own portfolio.
Start your 7-day free trialAbout Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.